Creatine kinase, platelet aggregation, and bleeding risk in women with uterine leiomyomas - Creatine kinase and bleeding risk

Academisch Medisch Centrum0 个研究点目标入组 32 人开始时间: 待定最近更新: 2024年2月28日

适应症

试验速览

暂无简介。

•Main study:
•20 premenopausal women aged 18-50 years, visiting the gynaecology outpatient clinic with uterine leiomyomas and heavy menstrual bleeding, and women without leiomyomas and normal menstrual bleeding, forming the control group. ;Pilot study:
•12 premenopausal female volunteers, 18-50 years:
•a. 8 women with heavy menstrual blood loss;
•- without treatment for the menstrual blood loss (n=2)
•- with plasmin inhibitor treatment for the menstrual blood loss (n=2)
•- with DOAC-induced heavy menstrual blood loss (n=2)
•- with VKA-induced heavy menstrual blood loss (n=2);
•b. 2 women normal menstrual blood loss;
•c. 2 women postpartum.

•Main study:
•Smoking, usage of NSAID, antiplatelet drugs and anticoagulants, hormone therapy or hormone supplements in 4 weeks prior to participation. Usage of CK-increasing drugs, such as statins, in the three months prior to participation. Glucose, lipid spectrum, thyroid, kidney or liver abnormalities, no history of secondary hypertension, (history of) cardiovascular disease including TIA and stroke; neuromuscular or endocrine disorders; vasculitis; HIV infection; malignancies; infectious hepatitis, bleeding disorders (other than heavy menstrual bleeding). ;Pilot study:
•Usage of CK-increasing drugs, such as statins, in the three months prior to participation. Glucose, lipid spectrum, thyroid, kidney or liver abnormalities, neuromuscular or endocrine disorders; HIV infection; infectious hepatitis, bleeding disorders (other than heavy menstrual bleeding).

发起方